Genscript Biotech Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Genscript Biotech Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 27 May 2022 | Lorem |
| Legend/Janssen’s CAR-T therapy asset cilta-cel potentially faces distribution, toxicity issues for multiple myeloma though FDA approval likely | 05 Nov 2021 | Adam Zamecnik |
| Nanjing Legend’s myeloma CAR-T yields comparable data to bluebird’s bb2121, but bluebird-Celgene partnership offers bigger boost – experts | 07 Jul 2017 | Alaric DeArment |
| Staurus employs GenScript for preclinical antibody manufacturing, signs licensing agreement - exec | 31 Aug 2016 | Alissa Fleck |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward